Vertex is under escalating pressure in the UK to give way on the pricing of its cystic fibrosis drug Orkambi (ivacaftor/lumacaftor) following a parliamentary debate on whether the government should issue a compulsory license for the drug. Steve Brine, parliamentary under secretary of state for public health and primary care, admitted that the government has already taken legal advice on whether this could be an option to provide access to treatment.
The debate came shortly after a patient-led activist group, Just Treatment, wrote to prime minister Teresa May and secretary of...








